Pilot Grant Program

试点资助计划

• 批准号: 10618388
• 负责人: Daniel E Voth
• 金额: $ 22.8万
• 依托单位: UNIV OF ARKANSAS FOR MED SCIS
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-05 至 2027-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10618388
• 关键词: 2019-nCoV; Address; Anti-Infective Agents; Antibiotic Resistance; Area; Arkansas; Bacteria; Centers of Research Excellence; Clinical; Collaborations; Communicable Diseases; Development; Diagnostic Procedure; Elements; Ensure; Equation; Foundations; Funding; Goals; Grant; Growth; Health; Howard Temin Award; Human; Immune response; Immunology; Individual; Infection; Inflammatory Response; Institution; Medical; Medicine; Microbiology; Mission; National Institute of General Medical Sciences; Parasites; Pathogenesis; Pharmaceutical Preparations; Phase; Play; Predisposition; Prevalence; Property; Publications; Research; Research Infrastructure; Research Personnel; Research Support; Science; Scientist; Side; Therapeutic; Therapeutic Intervention; Universities; Variant; Virus; adverse outcome; antimicrobial drug; biomaterial development; comorbidity; improved; innovation; interest; microbial; novel; pathogen; pathogenic microbe; programs; prophylactic; recruit; recruitment science; resistant strain; response; success; vaccine development

PROJECT SUMMARY/ABSTRACT A primary means of research support for investigators in the Center for Microbial Pathogenesis and Host Inflammatory Responses (CMPHIR) in Phase III will be the NIGMS-funded Pilot Grant Program (PGP), supplemented with institutional funds ($100,000 per year for each year) to support a Director's Innovation Fund. The focus will be on identifying new investigators with research interests consistent with the scientific theme of the CMPHIR. Support will be provided for projects that clearly fit within the scientific scope of the CMPHIR, with a particular emphasis on investigators whose research is potentially synergistic with existing CMPHIR investigators, thereby maximizing opportunities for the development of synergistic collaborations. We will also continue the efforts we started in Phase II to support projects that address issues in infectious disease in the most comprehensive fashion possible and one that can be integrated with the experimental foundation built in Phases I and II. Included among specific areas of interest are projects investigating improved diagnostic methods, the development of more effective antimicrobial drugs, the potential to repurpose approved drugs for infectious disease applications, vaccine development, the development of biomaterials with anti-infective properties, and understanding the impact of host comorbidities on the susceptibility to infection and the response to therapeutic intervention. In addition, the PGP and Director's Innovation Fund will be used in support of highly strategic external recruitment by other research units at UAMS recruiting new investigators with research interests consistent with the scientific theme of the CMPHIR. This will allow the CMPHIR to continue to grow and mature into a self-sustaining Center of Biomedical Research Excellence as we move forward into Phase III and beyond.

项目摘要/摘要 微生物发病机理和宿主中心研究人员的研究支持手段 第三阶段的炎症反应（CMPHIR）将是NIGMS资助的试点赠款计划（PGP）， 补充机构资金（每年每年100,000美元），以支持董事的创新基金。 重点将放在确定具有与研究兴趣的新调查人员有关的研究者 cmphir。将为明显适合CMPhir科学范围的项目提供支持，并提供 特别强调研究人员的研究可能与现有的CMPHIR具有协同作用 调查人员，从而最大程度地开发了协同合作的机会。我们也会 继续我们在第二阶段开始的努力，以支持解决传染病问题的项目 最全面的时尚，并且可以与内置的实验基础集成 第一阶段和第二阶段。在特定感兴趣的领域中包括项目，调查改进的诊断 方法，开发更有效的抗菌药物，重新利用批准的药物的潜力 传染病的应用，疫苗开发，具有抗感染的生物材料的发展 特性，并了解宿主合并症对感染易感性和反应的影响 进行治疗干预。此外，PGP和导演的创新基金将用于高度支持 UAMS的其他研究部门的战略外部招聘 兴趣与CMPHIR的科学主题一致。这将使cmphir继续增长和 当我们进入第三阶段时，成熟成为一个自我维持的生物医学研究中心 超过。